Research published on February 9, 2024, in the journal Gastroenterology highlights significant variations in disease patterns among Hispanic patients suffering from inflammatory bowel disease (IBD). The...
Enveda Biosciences, based in Boulder, has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its drug candidate, ENV-6946, aimed...
Boulder-based Enveda Biosciences has received clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its drug candidate, ENV-6946, aimed at treating...
